Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Medication

1. Lleo A, Marzorati S, Anaya JM, Gershwin ME. Primary biliary cholangitis: a comprehensive overview. Hepatol Int. 2017 Nov. 11(6):485-99. [QxMD MEDLINE Link].

2. American Liver Foundation. Primary biliary cholangitis (PBC, primary biliary cirrhosis). March 29, 2016. Available at http://www.liverfoundation.org/abouttheliver/info/pbc/. Accessed: June 3, 2016.

3. Ahrens EH Jr, Payne MA, Kunkel HG, Eisenmenger WJ, Blondheim SH. Primary biliary cirrhosis. 1950. Medicine (Baltimore). 1994 Sep. 73(5):264-78; discussion 278-80. [QxMD MEDLINE Link].

4. Solis Herruzo JA, Solis Munoz P, Munoz Yague T. The pathogenesis of primary biliary cirrhosis. Rev Esp Enferm Dig. 2009 Jun. 101(6):413-23. [QxMD MEDLINE Link].

5. Selmi C, Gershwin ME. The role of environmental factors in primary biliary cirrhosis. Trends Immunol. 2009 Aug. 30(8):415-20. [QxMD MEDLINE Link].

6. McNally RJ, Ducker S, James OF. Are transient environmental agents involved in the cause of primary biliary cirrhosis? Evidence from space-time clustering analysis. Hepatology. 2009 Oct. 50(4):1169-74. [QxMD MEDLINE Link].

7. Pandit S, Samant H. Primary biliary cholangitis. StatPearls [Internet]. 2021 Jan. [QxMD MEDLINE Link]. [Full Text].

8. Tanaka A. Current understanding of primary biliary cholangitis. Clin Mol Hepatol. 2021 Jan. 27(1):1-21. [QxMD MEDLINE Link]. [Full Text].

9. Ricci P, Therneau TM, Malinchoc M, et al. A prognostic model for the outcome of liver transplantation in patients with cholestatic liver disease. Hepatology. 1997 Mar. 25(3):672-7. [QxMD MEDLINE Link].

10. Mijic M, Saric I, Delija B, et al. Pretransplant evaluation and liver transplantation outcome in PBC patients. Can J Gastroenterol Hepatol. 2022. 2022:7831165. [QxMD MEDLINE Link]. [Full Text].

11. Bjornsson E, Kalaitzakis E, Neuhauser M, et al. Fatigue measurements in patients with primary biliary cirrhosis and the risk of mortality during follow-up. Liver Int. 2010 Feb. 30(2):251-8. [QxMD MEDLINE Link].

12. Mendes FD, Kim WR, Pedersen R, et al. Mortality attributable to cholestatic liver disease in the United States. Hepatology. 2008 Apr. 47(4):1241-7. [QxMD MEDLINE Link].

13. Younossi ZM, Bernstein D, Shiffman ML, et al. Diagnosis and management of primary biliary cholangitis. Am J Gastroenterol. 2019 Jan. 114(1):48-63. [QxMD MEDLINE Link].

14. Niro GA, Poli F, Andriulli A, et al. TNF-alpha polymorphisms in primary biliary cirrhosis: a northern and southern Italian experience. Ann N Y Acad Sci. 2009 Sep. 1173:557-63. [QxMD MEDLINE Link].

15. Onofrio FQ, Hirschfield GM, Gulamhusein AF. A practical review of primary biliary cholangitis for the gastroenterologist. Gastroenterol Hepatol (N Y). 2019 Mar. 15(3):145-54. [QxMD MEDLINE Link]. [Full Text].

16. Drebber U, Mueller JJ, Klein E, et al. Liver biopsy in primary biliary cirrhosis: clinicopathological data and stage. Pathol Int. 2009 Aug. 59(8):546-54. [QxMD MEDLINE Link].

17. Scheuer P. Primary biliary cirrhosis. Proc R Soc Med. 1967 Dec. 60(12):1257-60. [QxMD MEDLINE Link]. [Full Text].

18. Charatcharoenwitthaya P, Pimentel S, Talwalkar JA, et al. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl. 2007 Sep. 13(9):1236-45. [QxMD MEDLINE Link].

19. Tsuda M, Moritoki Y, Lian ZX, et al. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology. 2012 Feb. 55(2):512-21. [QxMD MEDLINE Link].

20. US Food and Drug Administration. FDA approves Ocaliva for rare, chronic liver disease. May 31, 2016. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm503964.htm. Accessed: June 1, 2016.

21. Edwards JE, LaCerte C, Pheng LH, et al. Sa1576 Exposure-response relationship of obeticholic acid for alkaline phosphatase and total bilirubin in patients with primary biliary cirrhosis (PBC). Poster presented at Digestive Disease Week; San Diego, California; May 21, 2016.

22. Nevens F, Andreone P, Mazzella G, et al, for the POISE Study Group. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016 Aug 18. 375(7):631-43. [QxMD MEDLINE Link]. [Full Text].

23. Levy C, Manns M, Hirschfield G. New treatment paradigms in primary biliary cholangitis. Clin Gastroenterol Hepatol. 2023 Jul. 21(8):2076-87. [QxMD MEDLINE Link]. [Full Text].

24. Rudic JS, Giljaca V, Krstic MN, Bjelakovic G, Gluud C. Bisphosphonates for osteoporosis in primary biliary cirrhosis. Cochrane Database Syst Rev. 2011 Dec 7. 12:CD009144. [QxMD MEDLINE Link].

25. Neff GW, O'Brien CB, Reddy KR, et al. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol. 2002 Aug. 97(8):2117-9. [QxMD MEDLINE Link].

26. Medina-Morales E, Ismail M, Barba Bernal R, et al. Two decades of liver transplants for primary biliary cholangitis: a comparative study of living donors vs. deceased donor liver transplantations. J Clin Med. 2023 Oct 15. 12(20):6536. [QxMD MEDLINE Link]. [Full Text].

27. [Guideline] Hirschfield GM, Dyson JK, Alexander GJM, et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut. 2018 Sep. 67(9):1568-94. [QxMD MEDLINE Link]. [Full Text].

28. Balasubramaniam K, Grambsch PM, Wiesner RH, et al. Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study. Gastroenterology. 1990 Jun. 98(6):1567-71. [QxMD MEDLINE Link].

29. Ballardini G, Mirakian R, Bianchi FB, et al. Aberrant expression of HLA-DR antigens on bileduct epithelium in primary biliary cirrhosis: relevance to pathogenesis. Lancet. 1984 Nov 3. 2(8410):1009-13. [QxMD MEDLINE Link].

30. Burroughs AK, Rosenstein IJ, Epstein O, et al. Bacteriuria and primary biliary cirrhosis. Gut. 1984 Feb. 25(2):133-7. [QxMD MEDLINE Link].

31. Bush A, Mitchison H, Walt R, et al. Primary biliary cirrhosis and ulcerative colitis. Gastroenterology. 1987 Jun. 92(6):2009-13. [QxMD MEDLINE Link].

32. Calmus Y, Gane P, Rouger P, et al. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology. 1990 Jan. 11(1):12-5. [QxMD MEDLINE Link].

33. Christensen E, Crowe J, Doniach D, et al. Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology. 1980 Feb. 78(2):236-46. [QxMD MEDLINE Link].

34. Culp KS, Fleming CR, Duffy J, et al. Autoimmune associations in primary biliary cirrhosis. Mayo Clin Proc. 1982 Jun. 57(6):365-70. [QxMD MEDLINE Link].

35. Dickson ER, Grambsch PM, Fleming TR, et al. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology. 1989 Jul. 10(1):1-7. [QxMD MEDLINE Link].

36. Elta GH, Sepersky RA, Goldberg MJ, et al. Increased incidence of hypothyroidism in primary biliary cirrhosis. Dig Dis Sci. 1983 Nov. 28(11):971-5. [QxMD MEDLINE Link].

37. Gershwin ME, Selmi C, Worman HJ, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology. 2005 Nov. 42(5):1194-202. [QxMD MEDLINE Link].

38. Hoffmann RM, Pape GR, Spengler U, et al. Clonal analysis of liver-derived T cells of patients with primary biliary cirrhosis. Clin Exp Immunol. 1989 May. 76(2):210-5. [QxMD MEDLINE Link].

39. Janes CH, Dickson ER, Okazaki R, et al. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest. 1995 Jun. 95(6):2581-6. [QxMD MEDLINE Link].

40. Jones DE, Metcalf JV, Collier JD, et al. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology. 1997 Nov. 26(5):1138-42. [QxMD MEDLINE Link].

41. Kaplan MM, Elta GH, Furie B, et al. Fat-soluble vitamin nutriture in primary biliary cirrhosis. Gastroenterology. 1988 Sep. 95(3):787-92. [QxMD MEDLINE Link].

42. Keller DM. Beta blockers ameliorate GI permeability in cirrhosis. Medscape Medical News from WebMD. May 2, 2013. Available at http://www.medscape.com/viewarticle/803542. Accessed: May 14, 2013.

43. Kim WR, Lindor KD, Locke GR 3rd, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology. 2000 Dec. 119(6):1631-6. [QxMD MEDLINE Link].

44. Klein R, Huizenga JR, Gips CH, et al. Antimitochondrial antibody profiles in patients with primary biliary cirrhosis before orthotopic liver transplantation and titres of antimitochondrial antibody-subtypes after transplantation. J Hepatol. 1994 Feb. 20(2):181-9. [QxMD MEDLINE Link].

45. Lacerda MA, Ludwig J, Dickson ER, et al. Antimitochondrial antibody-negative primary biliary cirrhosis. Am J Gastroenterol. 1995 Feb. 90(2):247-9. [QxMD MEDLINE Link].

46. Liermann Garcia RF, Evangelista Garcia C, et al. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology. 2001 Jan. 33(1):22-7. [QxMD MEDLINE Link].

47. Lindor K, Dickson R. Primary biliary cirrhosis. Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff's Diseases of the Liver. 8th ed. Lippincott-Raven: Philadelphia; 1999. Vol 1: 679-92.

48. Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol. 1994 Jun. 20(6):707-13. [QxMD MEDLINE Link].

49. Mang FW, Michieletti P, O'Rourke K, et al. Primary biliary cirrhosis, sicca complex, and dysphagia. Dysphagia. 1997 Summer. 12(3):167-70. [QxMD MEDLINE Link].

50. Marx WJ, O'Connell DJ. Arthritis of primary biliary cirrhosis. Arch Intern Med. 1979 Feb. 139(2):213-6. [QxMD MEDLINE Link].

51. Nakanuma Y, Tsuneyama K, Kono N, et al. Biliary epithelial expression of pyruvate dehydrogenase complex in primary biliary cirrhosis: an immunohistochemical and immunoelectron microscopic study. Hum Pathol. 1995 Jan. 26(1):92-8. [QxMD MEDLINE Link].

52. Newton JL, Gibson GJ, Tomlinson M, Wilton K, Jones D. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. Hepatology. 2006 Jul. 44(1):91-8. [QxMD MEDLINE Link].

53. Pares A, Rimola A, Bruguera M, et al. Renal tubular acidosis in primary biliary cirrhosis. Gastroenterology. 1981 Apr. 80(4):681-6. [QxMD MEDLINE Link].

54. Parikh-Patel A, Gold E, Mackay IR, et al. The geoepidemiology of primary biliary cirrhosis: contrasts and comparisons with the spectrum of autoimmune diseases. Clin Immunol. 1999 May. 91(2):206-18. [QxMD MEDLINE Link].

55. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology. 2006 Mar. 130(3):715-20. [QxMD MEDLINE Link].

56. Reynolds TB, Denison EK, Frankl HD, Lieberman FL, Peters RL. Primary biliary cirrhosis with scleroderma, Raynaud's phenomenon and telangiectasia. New syndrome. Am J Med. 1971 Mar. 50(3):302-12. [QxMD MEDLINE Link].

57. Roll J, Boyer JL, Barry D, et al. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med. 1983 Jan 6. 308(1):1-7. [QxMD MEDLINE Link].

58. Ros E, Garcia-Puges A, Reixach M, et al. Fat digestion and exocrine pancreatic function in primary biliary cirrhosis. Gastroenterology. 1984 Jul. 87(1):180-7. [QxMD MEDLINE Link].

59. Rutan G, Martinez AJ, Fieshko JT, et al. Primary biliary cirrhosis, Sjogren's syndrome, and transverse myelitis. Gastroenterology. 1986 Jan. 90(1):206-10. [QxMD MEDLINE Link].

60. Selinger S, Tsai J, Pulini M, et al. Autoimmune thrombocytopenia and primary biliary cirrhosis with hypoglycemia and insulin receptor autoantibodies. A case report. Ann Intern Med. 1987 Nov. 107(5):686-8. [QxMD MEDLINE Link].

61. Shapiro JM, Smith H, Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut. 1979 Feb. 20(2):137-40. [QxMD MEDLINE Link].

62. Thomas PK, Walker JG. Xanthomatous neuropathy in primary biliary cirrhosis. Brain. 1965 Dec. 88(5):1079-88. [QxMD MEDLINE Link].

63. Yamada G, Hyodo I, Tobe K, et al. Ultrastructural immunocytochemical analysis of lymphocytes infiltrating bile duct epithelia in primary biliary cirrhosis. Hepatology. 1986 May-Jun. 6(3):385-91. [QxMD MEDLINE Link].

64. [Guideline] Hirschfield GM, Beuers U, Corpechot C, et al, for the European Association for the Study of the Liver. EASL clinical practice guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017 Jul. 67(1):145-72. [QxMD MEDLINE Link].

65. [Guideline] Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019 Jan. 69(1):394-419. [QxMD MEDLINE Link]. [Full Text].

66. Younossi ZM, Bernstein D, Shiffman ML, et al. Diagnosis and management of primary biliary cholangitis. Am J Gastroenterol. 2019 Jan. 114(1):48-63. [QxMD MEDLINE Link].

Nikolaos T Pyrsopoulos, MD, PhD, MBA, FACP, AGAF, FAASLD, FRCP(Edin) Professor and Chief, Division of Gastroenterology and Hepatology, Professor of Physiology, Pharmacology, and Neuroscience, Medical Director of Liver Transplantation, Rutgers New Jersey Medical School

Nikolaos T Pyrsopoulos, MD, PhD, MBA, FACP, AGAF, FAASLD, FRCP(Edin) is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Liver Foundation, American Medical Association, American Society for Gastrointestinal Endoscopy, American Society of Transplantation, International Liver Transplantation Society, Transplantation Society

Disclosure: Received research grant from: GRIFOLS. BAYER, DURECT, INTERCEPT, BEIGENE, BMS.

Ranya Selim, MD Gastroenterologist/Transplant Hepatologist

Ranya Selim, MD is a member of the following medical societies: American College of Gastroenterology

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

BS Anand, MD Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

BS Anand, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

K Rajender Reddy, MD, FACP, FACG Ruimy Family President's Distinguished Professor of Medicine, Professor of Medicine in Surgery, Director of Hepatology, Medical Director of Liver Transplantation, Hospital of the University of Pennsylvania

K Rajender Reddy, MD, FACP, FACG is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, Florida Medical Association

Disclosure: Nothing to disclose.

George Y Wu, MD, PhD Professor, Department of Medicine, Director, Hepatology Section, Herman Lopata Chair in Hepatitis Research, University of Connecticut School of Medicine

George Y Wu, MD, PhD is a member of the following medical societies: American Association for the Study of Liver Diseases, American Gastroenterological Association, American Medical Association, American Society for Clinical Investigation, Association of American Physicians

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article